Maze Therapeutics, Inc. Common Stock (NASDAQ:MAZE) — Market Cap & Net Worth
Market Cap & Net Worth: Maze Therapeutics, Inc. Common Stock (MAZE)
Maze Therapeutics, Inc. Common Stock (NASDAQ:MAZE) has a market capitalization of $1.37 Billion ($1.37 Billion) as of September 26, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7640 globally and #2276 in its home market, demonstrating a 11.13% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Maze Therapeutics, Inc. Common Stock's stock price $26.05 by its total outstanding shares 55549168 (55.55 Million). Also see MAZE current and non-current assets for a full breakdown of the balance sheet.
Maze Therapeutics, Inc. Common Stock Market Cap History: 2025 to 2026
Maze Therapeutics, Inc. Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $2.30 Billion to $1.45 Billion (34.64% CAGR). Also see MAZE cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Maze Therapeutics, Inc. Common Stock is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.64 Trillion | 0.05% | #221 of 976 |
Weight: Maze Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Maze Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Maze Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MAZE share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MAZE by Market Capitalization
Companies near Maze Therapeutics, Inc. Common Stock in the global market cap rankings as of September 26, 2026. Review MAZE intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Maze Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #339 globally with a market cap of $79.70 Billion USD.
- CSL Ltd (AU:CSL): Ranked #453 globally with a market cap of $60.74 Billion USD ( AU$85.85 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #507 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $526.19 |
| #339 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.70 Billion | $788.04 |
| #453 | CSL Ltd | AU:CSL | $60.74 Billion | AU$176.95 |
| #507 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $198.88 |
Maze Therapeutics, Inc. Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Maze Therapeutics, Inc. Common Stock's market cap moved from $2.30 Billion to $ 1.45 Billion, with a yearly change of 34.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.45 Billion | -37.12% |
| 2025 | $2.30 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 26th, 2026 the market cap of Maze Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.37 Billion USD |
| MoneyControl | $1.37 Billion USD |
| MarketWatch | $1.37 Billion USD |
| marketcap.company | $1.37 Billion USD |
| Reuters | $1.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral s… Read more